Latest Insider Transactions at Quest Diagnostics Inc (DGX)
This section provides a real-time view of insider transactions for Quest Diagnostics Inc (DGX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of QUEST DIAGNOSTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of QUEST DIAGNOSTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 17
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
4,643
-10.86%
|
$789,310
$170.0 P/Share
|
|
Mar 05
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
5,370
-7.31%
|
$934,380
$174.13 P/Share
|
|
Mar 04
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,823
-16.13%
|
$315,379
$173.74 P/Share
|
|
Mar 04
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,317
+32.0%
|
$919,841
$173.74 P/Share
|
|
Mar 04
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,906
-8.37%
|
$675,738
$173.74 P/Share
|
|
Mar 04
2025
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,549
+15.48%
|
$1,478,977
$173.74 P/Share
|
|
Mar 04
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
592
-1.53%
|
$103,600
$175.79 P/Share
|
|
Mar 04
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
2,280
-9.73%
|
$394,440
$173.74 P/Share
|
|
Mar 04
2025
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
5,674
+19.5%
|
$981,602
$173.74 P/Share
|
|
Mar 04
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
1,879
-12.53%
|
$325,067
$173.74 P/Share
|
|
Mar 04
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
4,434
+22.82%
|
$767,082
$173.74 P/Share
|
|
Mar 04
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
31,656
-15.95%
|
$5,476,488
$173.74 P/Share
|
|
Mar 04
2025
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
61,917
+23.78%
|
$10,711,641
$173.74 P/Share
|
|
Mar 04
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
5,010
-6.39%
|
$866,730
$173.74 P/Share
|
|
Mar 04
2025
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
10,380
+11.69%
|
$1,795,740
$173.74 P/Share
|
|
Mar 04
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
716
-1.04%
|
$125,300
$175.79 P/Share
|
|
Mar 04
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-2.46%
|
$149,991
$173.74 P/Share
|
|
Mar 04
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,711
+4.63%
|
$296,003
$173.74 P/Share
|
|
Mar 04
2025
|
Sam Samad Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,684
-22.56%
|
$1,329,332
$173.74 P/Share
|
|
Mar 04
2025
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
13,884
+28.96%
|
$2,401,932
$173.74 P/Share
|
|
Mar 03
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
322
-0.83%
|
$55,706
$173.74 P/Share
|
|
Mar 03
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
106
-0.59%
|
$18,338
$173.74 P/Share
|
|
Mar 03
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
992
-8.58%
|
$171,616
$173.74 P/Share
|
|
Mar 03
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,662
-1.2%
|
$287,526
$173.74 P/Share
|
|
Mar 03
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
394
-0.57%
|
$68,162
$173.74 P/Share
|
|
Mar 03
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,692
-4.81%
|
$292,716
$173.74 P/Share
|
|
Feb 27
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
824
-1.18%
|
$141,728
$172.61 P/Share
|
|
Feb 27
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
528
-1.33%
|
$90,816
$172.61 P/Share
|
|
Feb 26
2025
|
Sam Samad Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
869
-4.13%
|
$148,599
$171.75 P/Share
|
|
Feb 26
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
455
-0.65%
|
$77,805
$171.75 P/Share
|
|
Feb 26
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
233
-1.98%
|
$39,843
$171.75 P/Share
|
|
Feb 26
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-1.27%
|
$39,159
$171.75 P/Share
|
|
Feb 26
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
286
-0.72%
|
$48,906
$171.75 P/Share
|
|
Feb 26
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,966
-2.1%
|
$507,186
$171.75 P/Share
|
|
Feb 26
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
214
-3.45%
|
$36,594
$171.75 P/Share
|
|
Feb 26
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
88
-0.25%
|
$15,048
$171.75 P/Share
|
|
Feb 20
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
899
-1.26%
|
$152,830
$170.99 P/Share
|
|
Feb 20
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
604
-1.49%
|
$102,680
$170.99 P/Share
|
|
Feb 19
2025
|
Sam Samad Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,031
-4.67%
|
$174,239
$169.71 P/Share
|
|
Feb 19
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
535
-0.74%
|
$90,415
$169.71 P/Share
|
|
Feb 19
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
287
-2.38%
|
$48,503
$169.71 P/Share
|
|
Feb 19
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Open market or private sale
|
Direct |
320
-1.74%
|
$54,080
$169.71 P/Share
|
|
Feb 19
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
374
-0.92%
|
$63,206
$169.71 P/Share
|
|
Feb 19
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,936
-2.04%
|
$496,184
$169.71 P/Share
|
|
Feb 19
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
242
-3.76%
|
$40,898
$169.71 P/Share
|
|
Feb 19
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-0.28%
|
$16,731
$169.71 P/Share
|
|
Feb 12
2025
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,538
+17.05%
|
-
|
|
Feb 12
2025
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
18,149
+11.18%
|
-
|
|
Feb 12
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
454
+1.27%
|
-
|
|
Feb 12
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,815
+21.99%
|
-
|